Literature DB >> 12540276

Regulation of microglia - potential new drug targets in the CNS.

Håkan Aldskogius1.   

Abstract

Microglia respond to any disturbance in the CNS which poses a threat to physiological homeostasis. Although these responses are secondary, mainly to neuronal alterations, the way the microglial response evolves in many situations promotes further damage to the CNS. The list of clinical conditions in which this situation is a major problem is continuously growing and includes neurodegenerative diseases, stroke, trauma, demyelinating disorders and neuropathic pain. The significance of microglia for the pathogenesis of neurological and neuropsychiatric conditions has led to a rapidly expanding search for therapeutic possibilities to regulate microglial activity. As will be clear from this review, treatments which are currently available appear to offer some positive effects but are still far from satisfactory. A major challenge is to understand the mechanisms that determine whether activated microglia will develop into a cytotoxic or a cytoprotective component.

Entities:  

Year:  2001        PMID: 12540276     DOI: 10.1517/14728222.5.6.655

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

Review 1.  Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.

Authors:  Andrea Lippoldt; Andreas Reichel; Ursula Moenning
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  ATP receptors gate microglia signaling in neuropathic pain.

Authors:  Tuan Trang; Simon Beggs; Michael W Salter
Journal:  Exp Neurol       Date:  2011-11-16       Impact factor: 5.330

3.  Toxic effect of methamphetamine on the retina of CD1 mice.

Authors:  Hong Lai; Huiyang Zeng; Cheng Zhang; Lin Wang; Mark O M Tso; Shenghan Lai
Journal:  Curr Eye Res       Date:  2009-09       Impact factor: 2.424

4.  Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture.

Authors:  Eva Bernhart; Manfred Kollroser; Gerald Rechberger; Helga Reicher; Akos Heinemann; Petra Schratl; Seth Hallström; Andrea Wintersperger; Christoph Nusshold; Trevor DeVaney; Klaus Zorn-Pauly; Roland Malli; Wolfgang Graier; Ernst Malle; Wolfgang Sattler
Journal:  Proteomics       Date:  2010-01       Impact factor: 3.984

5.  Differential modulation of microglia superoxide anion and thromboxane B2 generation by the marine manzamines.

Authors:  Alejandro M S Mayer; Mary L Hall; Sean M Lynch; Sarath P Gunasekera; Susan H Sennett; Shirley A Pomponi
Journal:  BMC Pharmacol       Date:  2005-03-11

6.  Blueberry Counteracts BV-2 Microglia Morphological and Functional Switch after LPS Challenge.

Authors:  Maria Giovanna De Caris; Maddalena Grieco; Elisa Maggi; Antonio Francioso; Federica Armeli; Luciana Mosca; Alessandro Pinto; Maria D'Erme; Patrizia Mancini; Rita Businaro
Journal:  Nutrients       Date:  2020-06-19       Impact factor: 5.717

Review 7.  Microglia control neuronal network excitability via BDNF signalling.

Authors:  Francesco Ferrini; Yves De Koninck
Journal:  Neural Plast       Date:  2013-09-05       Impact factor: 3.599

8.  1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype.

Authors:  Ioanna Plastira; Eva Bernhart; Madeleine Goeritzer; Helga Reicher; Vishwanath Bhat Kumble; Nora Kogelnik; Andrea Wintersperger; Astrid Hammer; Stefanie Schlager; Katharina Jandl; Akos Heinemann; Dagmar Kratky; Ernst Malle; Wolfgang Sattler
Journal:  J Neuroinflammation       Date:  2016-08-26       Impact factor: 9.587

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.